Clobetasol propionate
From Wikipedia, the free encyclopedia
 |
This article needs additional citations for verification. Please help improve this article by adding reliable references. Unsourced material may be challenged and removed. (May 2008) |
 |
|
|
Clobetasol propionate
|
|
| Systematic (IUPAC) name | |
| [17-(2'-chloroacetyl)- 9-fluoro-11-hydroxy-10,13,16-trimethyl- 3-oxo-6,7,8,11,12,14,15, 16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate | |
| Identifiers | |
| CAS number | |
| ATC code | D07 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C25H32ClFO5 |
| Mol. mass | 466.97 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
C (US) |
| Legal status |
Rx Only |
| Routes | ? |
Clobetasol propionate comes in ointment and emollient cream presentations. It is a very high potency topical corticosteroid that should not be used with occlusive dressings. It is recommended that treatment should be limited to 2 consecutive weeks and therapy should be discontinued when adequate results have been achieved. Clobetasol propionate is marketed and sold worldwide under numerous names including Temovate (US), Tenovate, Dermovate, Dermatovate, Butavate and, Movate.
It is used to treat diseases such as eczema and psoriasis, where it is used on the scalp and body. Also dispensed to counter auto-immune presentations, such as Alopecia areata (hair loss due to auto-immune diseases) and Lichen planus (auto immune skin nodules).
[edit] Presentations
- Clobetasol propionate ointment USP 0.05%, supplied in Olux 15 g, 30 g, 45 g, and 60 g tubes.
- Temovate & emollient 0.05%, supplied in 15 g (NDC 0173-0454-01), 30 g (NDC 0173-0454-02) and 60 g (NDC 0173-0454-03) tubes.
- Clobetasol propionate foam 0.05%
- Clobetasol propionate cream 0.05%
- Clobetasol propionate gel 0.05%
[edit] Possible side effects
- Acneform eruptions
- Allergic contact dermatitis
- Burning sensation
- Cracking and fissuring
- Cushing's syndrome
- Dryness
- Erythema
- Folliculitis
- Hypertrichosis
- Hypopigmentation
- Itching
- Irritation
- Miliaria
- Numbness of fingers
- Perioral dermatitis
- Pruritus
- Secondary infection
- Skin atrophy
- Skin maceration
- Stinging
- Striae
- Telangiectasia
Please note: According to the California Environmental Protection Agency (http://www.oehha.ca.gov/prop65/CRNR_notices/admin_listing/requests_info/referenced_docs/frpkg5r.html):
Studies in the rat following oral administration at dosage levels up to 50 mg/kg per day revealed that the females exhibited an increase in the number of resorbed embryos and a decrease in the number of living fetuses at the highest dose. Pregnancy: Teratogenic Effects (i.e., possibility of causing abnormailities in fetuses): Pregnancy Category C: Clobetasol propionate has not been tested for teratogenicity when applied topically; however, it is absorbed percutaneously, and when administered subcutaneously it was a significant teratogen in both the rabbit and mouse. Clobetasol propionate has greater teratogenic potential than steroids that are less potent.There are no adequate and well-controlled studies of the teratogenic effects of clobetasol propionate in pregnant women. Temovate Cream and Ointment should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
